Currently, several new ICIs have been developed to target PD-1 or PD-L1 that is known as a ligand to activate PD-1-elicited T cell exhaustion [15, 46–51] in many cancer types [52, 53] including bladder cancer. The gene discussed is CD274; the disease is cancer.